Przerzuty do pluc u chorych na niezaawansowanego raka endometrium

Abstract

Author(s): Pawel Blecharz, Marian Reinfuss, Krzysztof UrbaÅ?ski, Tomasz DÄ?browski, Elżbieta LuczyÅ?ska3, Wiktor Szatkowski

The aim of the study: The presentation of treatment approaches, outcomes and prognostic factors in patient with non-advanced endometrial cancer with lung metastases as the first symptom of treatment failure.

Material and methods: Sixty five percent (52/80) patients were diagnosed with isolated lung metastase and 15% (12/80) with multiple lesions. Moreover, in 20% (16/80) of patients dissemination to lung, liver, bones or brain was diagnosed. Surgical approach with adjuvant hormonotherapy was done in 35 pts with single lesion and palliative radiotherapy for bones or brain metastases was given for 7 pts. The most common therapy was hormono- or chemotherapy, used together with surgery or radiotherapy (42 pts) or alone (38 pts).

Results: Twelve months from diagnosis of dissemination survived 31,3% (25/80) of patients and 36 months – 7,5% (6/80) of patients. Thirty six months survivals were observed only in patients with single lung metastasis, treated with surgery plus hormonotherapy. The response rate for multiagent chemotherapy was 42,9% with 9-month median progression free survival. Prognostic factors for 12-month overall survivals in Cox analysis were time from diagnosis of endometrial cancer to dissemination (with cut-point for 24 months) and number of metastatic lesions (single vs. multiple).

Conclusions: Distant survivals for patients with disseminated non-advanced endometrial cancer can be achieved only in patients with single lung lesion thanks to surgical resection plus hormono- or chemotherapy. Palliative treatment of choice is multiagent chemotherapy with adriamycin, cipslatin and paclitaxel. Prognostic factor in patients with disseminated non-advanced endometrial cancer are time to dissemination and number of metastatic lesions.

Share this article

Editors List

  • S.SREEDHAR

    Submitted PhD thesis in Biotechnology at GITAM University, Vizag.

  • Yousef Alomi

    Yousef Alomi
    The Past Head, General Administration of Pharmaceutical Care at Ministry of Health,
    Saudi Arabia Critical Care/TPN
    Clinical Pharmacist Ministry of Health,
    Riyadh, Saudi Arabia.

  • Osamu Tanaka

    Osamu Tanaka
    Assistant Professor,
    Department of Radiation Oncology
    Asahi University Hospital
    Gifu city, Gifu, Japan

  • Maher Abdel Fattah Al-Shayeb

    Department of Surgical Sciences, Ajman University, UAE

  • Andrzej Zdziennicki

    Institute of Gynecology and Obstetrics, Medical University of Lodz, I Clinic of Gynecology and Gynecological Oncology (Lodz, Poland)

Google Scholar citation report
Citations : 61

Onkologia i Radioterapia received 61 citations as per Google Scholar report

Onkologia i Radioterapia peer review process verified at publons
Indexed In
  • Scimago
  • SCOPUS
  • MIAR
  • Euro Pub
  • Google Scholar
  • Medical Project Poland
  • PUBMED
  • Cancer Index
  • Gdansk University of Technology, Ministry Points 20